Practice parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the quality standards subcommittee of the American academy of neurology

Neurology

Volumn 74, Issue 11, 2010, Pages 924-931

  Zesiewicz, T A ^a   Sullivan, K L ^a   Arnulf, I ^b   Chaudhuri, K R ^c   Morgan, J C ^d   Gronseth, G S ^e   Miyasaki, J ^f   Iverson, D J ^g   Weiner, W J ^h  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF KANSAS   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Humboldt Neurological Medical Group Inc   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BOTULINUM TOXIN; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOMPERIDONE; FLUDROCORTISONE; INDOMETACIN; LEVODOPA; MACROGOL 3350; MELATONIN; METHYLPHENIDATE; MIDODRINE; MODAFINIL; PRAMIPEXOLE; PYRIDOSTIGMINE; ROPINIROLE; SILDENAFIL; THREO 3,4 DIHYDROXYPHENYLSERINE;

AKINESIA; ANXIETY; ANXIETY DISORDER; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; FATIGUE; HUMAN; HYPERSALIVATION; INSOMNIA; MOOD DISORDER; MORBIDITY; NARCOLEPSY; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT DISORDER; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SENSORY DYSFUNCTION; SLEEP DISORDER; URINE INCONTINENCE; AUTONOMIC NEUROPATHY; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; UNITED STATES;

AUTONOMIC NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; SLEEP DISORDERS; UNITED STATES;

EID: 77950475028     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d55f24     Document Type: Article

References (40)

1. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001;16:507-510.
2. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
3. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
4. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-1714. (Pubitemid 351644139)
5. Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2008;14:451-456.
6. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374.
7. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-936.
8. Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-1549.
9. Abate G, Polimeni RM, Cuccurullo F, Puddu P, Lenzi S. Effects of indomethacin on postural hypotension in Parkinsonism. BMJ 1979;2:1466-1468. (Pubitemid 10162310)
10. Wright RA, Kaufmann HC, Perera R, et al. A doubleblind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-124.
11. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003;74:1294-1298.
12. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-745.
13. Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-1453.
14. Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55:118-120. (Pubitemid 38067369)
15. Shimizu N, Matsumoto S, Mori Y, et al. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo 2007;53:609-612.
16. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease: a randomized placebo-controlled study. Mov Disord 2007;22:1239-1244.
17. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1176-1177.
18. Jost WH, Schimrigk K. The effect of cisapride on delayed colonic transit time in patients with idiopathic Parkinson's disease. Wien Klin Wochenschr 1994;106:673-676.
19. Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord 1993;8:339-343.
20. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006;21:115-116.
21. Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003;98:1439-1440.
22. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomized controlled trials. Drug Saf 2001;24:863-868.
23. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
24. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.
25. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.
26. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.
27. Leeman AL, O'Neill CJ, Nicholson PW, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987;24:637-643.
28. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol 1998;245(suppl 1):S15-S18.
29. Cassone VM. Effects of melatonin on vertebrate circadian systems. Trends Neurosci 1990;13:457-464.
30. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005;6:459-466.
31. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magal- hães MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease: a randomized, double blind, placebo-controlled study. J Neurol 2007;254:459-464.
32. Monaca C, Ozsancak C, Jacquesson JM, et al. Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. J Neurol 2004;251:214-218.
33. Iranzo A, Valldeoriola F, Santamaría J, Tolosa E, Rumià J. Sleep symptoms and polysomnographic architecture in advanced Parkinson's disease after chronic bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:661-664.
34. ArnulfI, Bejjani BP, Garma L, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000;55:1732-1734.
35. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002;59:421-424.
36. Högl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003;28: 1866-1870.
37. Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076.
38. Llana ME, Crismon ML. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc 1999;39:526-530.
39. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
40. Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, García-Sánchez C. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007;22:62-67.